Typewriter raises $56m Series A to progress non-viral gene therapy platform - Pharmaceutical Technology

Typewriter harnesses a non-viral approach as viral vectors increasingly come under the spotlight for their associated safety risks. Typewriter harnesses a non-viral approach as viral vectors increasingly come under the spotlight for their associated safety risks. Typewriter will use the funds to progress its non-viral gene therapy platform closer to the clinic. Credit: Natali _ Mis / Shutterstock.com. Biotech startup Typewriter Therapeutics has emerged from stealth with $56m in capital as it looks to progress its non-viral in vivo gene therapy platform closer to the clinic. The Series A funding round, which was led by big industry hitters RA Capital…

Source: Pharmaceutical Technology